BiotechTube

Obinutuzumab + Glofitamab + Pirtobrutinib

Phase 2Recruiting
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Mantle Cell Lymphoma

Conditions

Mantle Cell Lymphoma

Trial Timeline

Jun 11, 2024 → Jul 31, 2028

NCT ID
NCT06252675

About Obinutuzumab + Glofitamab + Pirtobrutinib

Obinutuzumab + Glofitamab + Pirtobrutinib is a phase 2 stage product being developed by Eli Lilly for Mantle Cell Lymphoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06252675. Target conditions include Mantle Cell Lymphoma.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT06252675Phase 2Recruiting

Competing Products

20 competing products in Mantle Cell Lymphoma

See all competitors
ProductCompanyStageHype Score
Pirtobrutinib + Brexucabtagene AutoleucelEli LillyPhase 2
52
enzastaurinEli LillyPhase 2
52
AbemaciclibEli LillyPhase 2
52
Pirtobrutinib + Ibrutinib + Acalabrutinib + ZanubrutinibEli LillyPhase 3
77
Pirtobrutinib + Rituximab + VenetoclaxEli LillyPhase 2
52
Pirtobrutinib and rituximabEli LillyPhase 2
52
gemcitabine + mitoxantrone + rituximabEli LillyPhase 2
52
Rituximab 375 mg/m^2 + Cyclophosphamide 750 mg/m^2 + Doxorubicin 50 mg/m^2 + VELCADE 1.3 mg/m^2 + Prednisone 100 mg/m^2 + Vincristine 1.4 mg/m^2Johnson & JohnsonPhase 3
77
VenetoclaxAbbViePhase 2
52
Ibrutinib + VenetoclaxAbbViePhase 2
52
ABT-199 and Ibrutinib CombinationAbbViePhase 1
33
Venetoclax Oral Tablet [Venclexta]AbbViePhase 2
52
Acalabrutinib capsuleAstraZenecaApproved
85
Acalabrutinib in combination with BR + Acalabrutinib in combination with VRAstraZenecaPhase 1
33
Acalabrutinib + Venetoclax + ObinutuzumabAstraZenecaPhase 1/2
41
Acalabrutinib + R-CHOP standard of care + Acalabrutinib combination with Rituximab + Acalabrutinib monotherapyAstraZenecaPhase 2
52
Acalabrutinib + Venetoclax + RituximabAstraZenecaPhase 2
52
Acalabrutinib + RituximabAstraZenecaPhase 2
52
Acalabrutinib Treatment A + Acalabrutinib Treatment B + Acalabrutinib Treatment C + Acalabrutinib Treatment DAstraZenecaPhase 1
33
Acalabrutinib + Lenalidomide + Rituximab + ObinutuzumabAstraZenecaPhase 2
52

Other Products from Eli Lilly

Insulin Glargine + Insulin Lispro Premix (mid-mixture and low-mixture)Approved
85
Olanzapine + PlaceboApproved
85
exenatide and sitagliptin + exenatide and placeboApproved
85
Tirzepatide + PlaceboApproved
85
tadalafilApproved
85